Astria Therapeutics to Participate in Virtual Fireside Chat at Upcoming H.C. Wainwright 1st Annual Hereditary Angioedema Conference

Rhea-AI Summary

Astria Therapeutics (NASDAQ:ATXS) announced its CEO, Jill C. Milne, will engage in a virtual fireside chat at the 1st Annual Hereditary Angioedema Conference on July 20 at 12:30 PM ET. The conference focuses on hereditary angioedema, a rare condition for which Astria is developing STAR-0215, a monoclonal antibody aimed at treating this disease. A live webcast will be available at this link, and an archived replay will be accessible on Astria's website for 30 days afterwards.

BOSTON--(BUSINESS WIRE)-- Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for hereditary angioedema and focused on life-changing therapies for rare and niche allergic and immunological diseases, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will participate in a virtual fireside chat at the upcoming H.C. Wainwright 1^st Annual Hereditary Angioedema Conference on Wednesday, July 20, at 12:30pm ET.

A webcast of the event can be accessed at the following link: https://journey.ct.events/view/519a557c-f4a1-4383-85fa-e0f4e35d70d4. An archived replay of the event will be available in the investors section of www.astriatx.com for 30 days following the event.

About Astria Therapeutics:

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Learn more about our company on our website, www.astriatx.com, or follow us on Twitter and Instagram @AstriaTx and on Facebook and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220714005129/en/

Investor relations:

Andrea Matthews

investors@astriatx.com

Media:

Elizabeth Higgins

media@astriatx.com

Source: Astria Therapeutics, Inc.

FAQ

What is the date and time of the Astria Therapeutics virtual fireside chat?

The virtual fireside chat will take place on July 20 at 12:30 PM ET.

Who is participating in the H.C. Wainwright Annual Conference?

Jill C. Milne, CEO of Astria Therapeutics, will participate in the conference.

What is STAR-0215 being developed for by Astria Therapeutics?

STAR-0215 is being developed as a treatment for hereditary angioedema.

Where can I watch the Astria Therapeutics conference webcast?

The webcast can be accessed at https://journey.ct.events/view/519a557c-f4a1-4383-85fa-e0f4e35d70d4.

How long will the archived replay of the virtual fireside chat be available?

The archived replay will be available for 30 days on Astria Therapeutics' website.